Drug Trial Radar · NCT06365918
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
Last checked: Nov 19, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Sep 30, 2024
Primary completion
Oct 2, 2024
Study completion Oct 2, 2024
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To find the recommended dose of the investigational drug VG2025 that can be given intraperitoneally (given directly into the abdominal cavity) to participants with advanced solid tumors.
Conditions
- Advanced Solid Tumor
- Carcinomatosis
Interventions
VG2025Drug
Given by Intraperitoneal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and adverse events (AEs)Time frame: Through study completion; an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.